Company Overview

Update
Founded:
2003
Headquarters:
Utrecht
Funding:
$70.20M
Categories:
Biotechnology

Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.

Description

Update

Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Board Members and Advisors (2)

Update

Funding Rounds (2) - $70.20M

Update

Investors (6)

Update

Offices/Locations (1)

Update
  • Office

    Padualaan 8 (postvak 133)

    Utrecht, 3584 CH

    NLD

Images (1)

Update
  • F81c924f5e540bbcd9f024ddfc368665